N-芴甲氧羰基-DL-正亮氨酸 | 144701-20-2

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 亮氨酸类衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: N-芴甲氧羰基-DL-正亮氨酸
• 中文别名: Fmoc-DL-正亮氨酸
• 英文名称: Fmoc-norleucine
• 英文别名: Fmoc-nLeu-OH；2-(9H-fluoren-9-ylmethoxycarbonylamino)hexanoic acid
• CAS: 144701-20-2
• 化学式: C₂₁H₂₃NO₄
• 分子量: 353.418
• InChiKey: VCFCFPNRQDANPN-UHFFFAOYSA-N

物化性质

• 沸点：
  565.6±33.0 °C(Predicted)
• 密度：
  1.209±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  26
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存储于室温下。

反应信息

• 作为反应物：
  描述：

  N-芴甲氧羰基-DL-正亮氨酸 在 N,N'-二环己基碳二亚胺 、 三氟乙酸 作用下， 以 正己烷 、 异丙醇 为溶剂， 反应 12.0h， 生成 Methyl (2S)-2-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}hexanoate
  参考文献：
  名称：

  使用直链淀粉衍生的手性固定相测定作为N-芴基甲氧基羰基衍生物的α-氨基酸及其甲基酯的化学和对映体纯度

  摘要：

  在衍生自直链淀粉衍生物的三个共价键合型手性固定相（CSP）上进行液相色谱对映体分离，同时测定α-氨基酸及其甲酯作为N-芴基甲氧基羰基（FMOC）衍生物的化学和对映体纯度。作为N-FMOC衍生物的α-氨基酸酯的对映体分离要好于相应的酸，尤其是对于CSP 1和2。对于一些市售消旋氨基酸甲酯中存在的化学杂质，如相应的消旋酸，观察到是0.49–17.50％。发现几种可商购的L-氨基酸甲酯的对映体杂质为0.03-0.58％，而相同分析物中存在的相应消旋酸的化学杂质为0.13-13.62％。

  DOI：

  10.1002/bkcs.11694
• 作为产物：
  描述：

  DL-正亮氨酸 、 9-芴甲基-N-琥珀酰亚胺基碳酸酯 在 phosphate buffer 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 N-芴甲氧羰基-DL-正亮氨酸
  参考文献：
  名称：

  Novel Selective Inhibitors of the Interaction of Individual Nuclear Hormone Receptors with a Mutually Shared Steroid Receptor Coactivator 2

  摘要：

  Nuclear hormone receptor (NR) signaling, currently a therapeutic target in multiple diseases, involves an ordered series of protein interactions to regulate transcription in response to changing hormone levels. Later steps in the process of ligand-dependent signaling are driven by a highly conserved interaction between the NRs and the steroid receptor coactivators (SRCs) that is effected by a conserved interaction motif (L1XXL2L3), known as an NR box. Using computational design and combinatorial chemistry, we have produced novel alpha-helical proteomimetics of the second NR box of SRC2 that exploit structural differences between human estrogen receptor alpha (hERalpha), human estrogen receptor beta (hERbeta), and human thyroid hormone receptor beta (hTRbeta). The resulting library sequentially replaced each leucine with non-natural side chains. Screening this library using a quantitative competition assay revealed compounds that selectively inhibit the interaction of SRC2-2 with each individual NR in preference to its interaction with the other NR. This approach generated highly selective compounds from one that had no specificity for a particular family member. These compounds represent the first family-member-selective competitive inhibitors of the protein interactions of transcription factors.

  DOI：

  10.1021/ja0348391

文献信息

• Methods for 20S Immunoproteasome and 20S Constitutive Proteasome Determination Based on SPRI Biosensors
  作者：Sankiewicz Anna、Markowska Agnieszka、Lukaszewski Zenon、Puzan Beata、Gorodkiewicz Ewa

  DOI：10.1007/s12195-017-0478-7

  日期：2017.4

  The 20S proteasome, released into the circulation, is a novel cancer biomarker. It exists in two forms: the constitutive proteasome (20Sc) and the immunoproteasome (20Si), which both have separate diagnostic significance. The aim of this work was to develop new methods for 20Si and 20Sc determination. Five alternative specific biosensors usable with the surface plasmon resonance imaging (SPRI) technique for 20Si determination have been developed. Specific 20Si entrapment on the biosensor surface from an analyzed solution was achieved by means of an immobilized specific 20Si receptor. Four of the biosensors contain newly synthesized specific 20Si receptors, while the fifth contains the inhibitor ONX 0914. A method for 20Sc determination using an SPRI biosensor containing PSI inhibitor has been developed. By the introduction of an inhibitor blocking 20Si, 20Sc is selectively determined. All of the methods developed for 20Si and 20Sc determination exhibit good selectivity and satisfactory precision, recoveries and dynamic response ranges. 20Si and 20Sc were determined in blood plasma samples from healthy donors and patients with acute leukemia. In the case of these patients 20Si was the major component, and its level was more than one order of magnitude higher than in the healthy donors.

  20S蛋白酶释放到循环中，是一种新型的癌症生物标志物。它存在两种形式：构成性蛋白酶（20Sc）和免疫蛋白酶（20Si），它们都具有单独的诊断意义。本研究的目的是开发新的方法来确定20Si和20Sc。已经开发了五种可用于20Si测定的具有特异性的替代性生物传感器，这些传感器可与表面等离子共振成像（SPRI）技术一起使用。通过固定化特异性的20Si受体，可以从分析溶液中实现特异性的20Si捕获在生物传感器表面上。其中四种生物传感器含有新合成的特异性20Si受体，而第五种含有抑制剂ONX 0914。已经开发了一种使用含有PSI抑制剂的SPRI生物传感器进行20Sc测定的方法。通过引入阻断20Si的抑制剂，可以选择性地确定20Sc。所有为20Si和20Sc测定开发的方法均具有良好的选择性和令人满意的精度、回收率和动态响应范围。从健康供体和急性白血病患者的血浆样本中测定了20Si和20Sc。在这些患者中，20Si是主要成分，其水平比健康供体高一个数量级以上。

• [EN] STAT DEGRADERS AND USES THEREOF<br/>[FR] AGENTS DE DÉGRADATION DE STAT ET LEURS UTILISATIONS
  申请人：KYMERA THERAPEUTICS INC

  公开号：WO2020206424A1

  公开（公告）日：2020-10-08

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用方法。
• NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF
  申请人：Boyd A. Vincent

  公开号：US20070021434A1

  公开（公告）日：2007-01-25

  The present dislcosure provides amide-based, non-nucleoside compounds having antiviral activity against Hepacivirus, such as hepatitis C virus (HCV), methods and intermediates for synthesizing such compounds, and methods of using the compounds in a variety of contexts, including in the treatment and prevention of viral infections. The present dislcosure also provides methods for identifying amide-based, non-nucleoside compounds having antiviral activity.

  本公开提供了基于酰胺的非核苷类化合物，具有抗Hepacivirus活性，例如丙型肝炎病毒（HCV），合成这类化合物的方法和中间体，以及在各种情境中使用这些化合物的方法，包括在治疗和预防病毒感染中的应用。本公开还提供了识别具有抗病毒活性的基于酰胺的非核苷类化合物的方法。
• COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE
  申请人：Cameron Dale Russell

  公开号：US20080171783A1

  公开（公告）日：2008-07-17

  The present disclosure provides amide-based, non-nucleoside compounds having an inhibitory activity against endogenous polymerases, such as polymerase alpha and polymerase gamma. This disclosure further provides uses of treating hyperproliferative diseases or disorders, such as benign or malignant neoplasms, and more specifically cancers that are sensitive to inhibition of polymerase alpha and polymerase gamma.

  本公开提供了基于酰胺的非核苷类化合物，具有对内源聚合酶（如聚合酶α和聚合酶γ）的抑制活性。本公开进一步提供了用于治疗过度增殖性疾病或疾病的用途，例如良性或恶性肿瘤，更具体地是对聚合酶α和聚合酶γ抑制敏感的癌症。
• [EN] DIASTEREOMERIC LINKING REAGENTS FOR NUCLEOTIDE PROBES<br/>[FR] RÉACTIFS DE LIAISON DIASTÉRÉOMÉRIQUES POUR SONDES NUCLÉOTIDIQUES
  申请人：BRENTANO BIOTECHNOLOGY ASS

  公开号：WO2021061154A1

  公开（公告）日：2021-04-01

  A versatile reagent with a non-nucleotide monomeric unit comprising an enantiomeric center and having a ligand, and first and second coupling groups that are linked to the non-nucleotide monomeric unit. Such a reagent permits preparation of versatile nucleotide/non-nucleotide polymers, having any desired sequence of nucleotide and non-nucleotide monomeric units, each of the latter of which bear a desired ligand. These polymers can, for example, be used as probes which can exhibit enhanced sensitivity and/or which are capable of detecting a genus of nucleotides each species of which has a common target nucleotide sequence of interest bridged by different sequences not of interest.

  一种多功能试剂，具有一个非核苷单体单元，包括一个对映中心和一个配体，以及与非核苷单体单元相连的第一和第二偶联基团。这种试剂可以制备多功能核苷酸/非核苷酸聚合物，具有任何所需的核苷酸和非核苷酸单体单元序列，其中每个后者都带有所需的配体。这些聚合物可以用作探针，可以展示增强的灵敏度和/或能够检测一类核苷酸，其中每个物种都有一个共同的感兴趣的靶核苷酸序列，通过不感兴趣的不同序列连接。